Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging

Background: Observational studies suggested that dementia risk in patients with rheumatoid arthritis (RA) is higher than in the general population. Objective: To examine the associations of RA with cognitive decline and dementia, and neuroimaging biomarkers of aging, Alzheimer’s disease, and vascular pathology in adult participants in the Mayo Clinic Study of Aging (MCSA). Methods: Participants with RA were matched 1:3 on age, sex, education, and baseline cognitive diagnosis to participants without RA. RA cases with MRI were also matched with non-cases with available MRI. All available imaging studies (i.e., amyloid and FDG PET, sMRI, and FLAIR) were included. The study included 104 participants with RA and 312 without RA (mean age (standard deviation, SD) 75.0 (10.4) years, 33% male and average follow-up (SD) 4.2 (3.8) years). Results: Groups were similar in cognitive decline and risk of incident dementia. Among participants with neuroimaging, participants with RA (n = 33) and without RA (n = 98) had similar amyloid burden and neurodegeneration measures, including regions sensitive to aging and dementia, but greater mean white matter hyperintensity volume relative to the total intracranial volume (mean (SD)% : 1.12 (0.57)% versus 0.76 (0.69)% of TIV, p = 0.01), and had higher mean (SD) number of cortical infarctions (0.24 (0.44) versus 0.05 (0.33), p = 0.02). Conclusion: Although cognitive decline and dementia risk were similar in participants with and without RA, participants with RA had more abnormal cerebrovascular pathology on neuroimaging. Future studies should examine the mechanisms underlying these changes and potential implications for prognostication and prevention of cognitive decline in RA.

[1]  A. Ogdie,et al.  Association between depression, anxiety, chronic pain, or opioid use and tumor necrosis factor inhibitor persistence in inflammatory arthritis , 2022, Clinical Rheumatology.

[2]  J. Piette,et al.  No association between rheumatoid arthritis and cognitive impairment in a cross-sectional national sample of older U.S. adults , 2021, BMC Rheumatology.

[3]  M. Mielke,et al.  Trends in incidence of dementia among patients with rheumatoid arthritis: A population-based cohort study. , 2021, Seminars in arthritis and rheumatism.

[4]  W. Rathmann,et al.  White matter hyperintensity volume in pre-diabetes, diabetes and normoglycemia , 2021, BMJ Open Diabetes Research & Care.

[5]  Jingjing Xu,et al.  Adalimumab ameliorates memory impairments and neuroinflammation in chronic cerebral hypoperfusion rats , 2021, Aging.

[6]  M. Raji,et al.  Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs , 2020, Clinical Rheumatology.

[7]  G. Kitas,et al.  Is There a Brain/Heart Interaction in Rheumatoid Arthritis and Seronegative Spondyloartropathies? A Combined Brain/Heart Magnetic Resonance Imaging Reveals the Answer , 2020, Current Rheumatology Reports.

[8]  Anthony J. Spychalla,et al.  Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. , 2020, Mayo Clinic proceedings.

[9]  E. Matteson,et al.  Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014 , 2020, Annals of the rheumatic diseases.

[10]  J. Lei,et al.  Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study , 2019, Alzheimer's Research & Therapy.

[11]  H. Choi,et al.  Rheumatoid arthritis and neurodegenerative dementia: a nested case-control study and a follow-up study using a national sample cohort , 2019, Clinical Rheumatology.

[12]  Yuan-Han Yang,et al.  Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients with Rheumatoid Arthritis? , 2019, Neurotherapeutics.

[13]  David T. Jones,et al.  Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. , 2019, JAMA.

[14]  O. Kim,et al.  Adalimumab improves cognitive impairment, exerts neuroprotective effects and attenuates neuroinflammation in an Aβ1-40-injected mouse model of Alzheimer's disease. , 2019, Cytotherapy.

[15]  P. Narongroeknawin,et al.  Disease activity is associated with cognitive impairment in patients with rheumatoid arthritis , 2019, Clinical Rheumatology.

[16]  J. Hanlon,et al.  American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults , 2019, Journal of the American Geriatrics Society.

[17]  S. Larsson,et al.  Clinical Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury: A Systematic Review and Meta-analysis , 2019, JAMA neurology.

[18]  B. McGuinness,et al.  The influence of TNF inhibitors on dementia incidence in patients with rheumatoid arthritis; an analysis from the BSRBR‐RA , 2018, International journal of geriatric psychiatry.

[19]  R. Grassi‐Oliveira,et al.  Cognitive impairment in rheumatoid arthritis: role of lymphocyte subsets, cytokines and neurotrophic factors , 2018, Clinical Rheumatology.

[20]  Chi-Ching Chang,et al.  Autoimmune rheumatic diseases increase dementia risk in middle-aged patients: A nationwide cohort study , 2018, PloS one.

[21]  S. Cumming,et al.  Cognitive Impairment in Rheumatoid Arthritis: A Systematic Review , 2018, Arthritis care & research.

[22]  Quincy M. Samus,et al.  Dementia prevention, intervention, and care , 2017, The Lancet.

[23]  Jong-Yi Wang,et al.  DMARD use is associated with a higher risk of dementia in patients with rheumatoid arthritis: A propensity score‐matched case–control study , 2017, Toxicology and applied pharmacology.

[24]  C. Cooper,et al.  Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients , 2017, Alzheimer's & dementia.

[25]  David T. Jones,et al.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease , 2017, Alzheimer's & Dementia.

[26]  S. Gautam,et al.  Treatment for Rheumatoid Arthritis and Risk of Alzheimer’s Disease: A Nested Case-Control Analysis , 2016, CNS Drugs.

[27]  J. Wardlaw,et al.  Cerebrovascular Disease in Rheumatic Diseases: A Systematic Review and Meta-Analysis , 2016, Stroke.

[28]  C. Thongprayoon,et al.  Rheumatoid arthritis and the risk of dementia: A systematic review and meta-analysis. , 2016, Neurology India.

[29]  Matthew L Senjem,et al.  Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings , 2015, Brain : a journal of neurology.

[30]  Robert A. Koeppe,et al.  The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.

[31]  P. Chowienczyk,et al.  Are Inflammation and Related Therapy Associated with All-Cause Dementia in a Primary Care Population? , 2015, Journal of Alzheimer's disease : JAD.

[32]  S. Cumming,et al.  A preliminary investigation of cognitive function in rheumatoid arthritis patients on long-term methotrexate treatment , 2013, Journal of health psychology.

[33]  B. Yawn,et al.  History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. , 2012, Mayo Clinic proceedings.

[34]  Scott M. Brue,et al.  Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. , 2012, International journal of epidemiology.

[35]  J. Aviña-Zubieta,et al.  Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies , 2012, Annals of the rheumatic diseases.

[36]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[37]  A. Silman,et al.  UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .

[38]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[39]  C. Jack,et al.  Blood Pressure and White-Matter Disease Progression in a Biethnic Cohort: Atherosclerosis Risk in Communities (ARIC) Study , 2010, Stroke.

[40]  V. Pankratz,et al.  The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics , 2008, Neuroepidemiology.

[41]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[42]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[43]  E. Tangalos,et al.  Neuropsychological tests' norms above age 55: COWAT, BNT, MAE token, WRAT-R reading, AMNART, STROOP, TMT, and JLO , 1996 .

[44]  E. Tangalos,et al.  Mayo's older americans normative studies: WAIS-R norms for ages 56 to 97 , 1992 .

[45]  James F. Malec,et al.  Mayo's older americans normative studies: Updated AVLT norms for ages 56 to 97 , 1992 .

[46]  E. Tangalos,et al.  The short test of mental status. Correlations with standardized psychometric testing. , 1991, Archives of neurology.

[47]  O. Spreen,et al.  A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary , 1991 .

[48]  Robert A. Bornstein,et al.  The Wechsler Memory Scale—Revised , 1990 .

[49]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[50]  P. Rubé,et al.  L’examen Clinique en Psychologie , 1959 .

[51]  R. Reitan.  Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .